Slide 1: First quarter financials
Conference call, 6 May 2009 2009 First quarter financials
Slide 2: First Quarter 2009 Highlights
FIRST QUARTER 2009 HIGHLIGHTS • Revenue € 183.7 million, up 6.9%, international sales grow by 11.7% • Operating income (EBIT) € 40.6 million, up 6.5% • Net Income € 27.6 million, up 9.3% • Acquisition of Herbacos-Bofarma in the Czech Republic • Subsequent events: Zanextra® (lercanidipine+enalapril)
Slide 3: Composition of Revenue
COMPOSITION OF REVENUE (million Euro) 1Q 2009 1Q 2008 Change % Italy 53.3 54.0 (1.4) France 34.7 33.6 3.2 Germany 13.4 11.7 14.9 Portugal 11.0 11.7 (5.7) Spain 6.6 6.5 2.0 United Kingdom 2.5 2.5 0.4 Other European countries 1.6 1.1 42.4 Russia, Turkey, other CEE countries 11.8 3.4 n.s. Other interna
Slide 4: Composition of Pharmaceutical Revenue
COMPOSITION OF PHARMACEUTICAL REVENUE Portugal 6.2% Spain 3.7% Germany 7.6% UK 1.4% Other European countries 0.9% Russia, Turkey, other CEE 6.7% France 19.6% Other international sales 16.9% Pharmaceutical Italy 30.1% Orphan Europe 6.8% chemicals 3.7% Pharmaceuticals 96.3% Data: First quarter 2009 To
Slide 5: Lercanidipine Sales
LERCANIDIPINE SALES (million Euro) 1Q 2009 1Q 2008 Change % DIRECT SALES 34.1 31.2 9.4 SALES TO LICENSEES 20.1 19.9 1.3 TOTAL LERCANIDIPINE SALES 54.3 51.1 6.3 4
Slide 6: First Quarter 2009 Results
FIRST QUARTER 2009 RESULTS (million Euro) 1Q 2009 1Q 2008 Change % Revenue 183.7 171.9 6.9 Gross Profit 123.5 116.1 6.4 as % of revenue 67.2% 67.6% SG&A Expenses 65.8 63.4 3.8 as % of revenue 35.8% 36.9% R&D Expenses 15.3 13.4 14.4 as % of revenue 8.3% 7.8% Other Income (Expense), net (1.8) (1.2) 47
Slide 7: Net Financial Position and Shareholder's Equity
NET FINANCIAL POSITION AND SHAREHOLDER’S EQUITY (million Euro) 31 Mar 2009 31 Dec 2008 Change Cash and short-term financial 62.8 95.0 (32.2) investments Bank overdrafts and short-term (62.2) (90.8) 28.7 loans Loans – due within one year (2.8) (2.2) (0.6) Loans – due after one year (83.7) (82.9) (0.8
Slide 8: 2009 Targets
2009 TARGETS 2008 2009 Actual Targets (million Euro) Revenue 689.6 ~750 R&D expenses 58.9 ~75 Operating income (EBIT) 144.7 ~155 Net Income 100.4 ~105 7
Slide 9: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finan